TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00688662

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ERCP with sphincterotomy
Description: cutting the biliary sphincter muscle (sphincterotomy)

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: ERCP without sphincterotomy
Description: ERCP with sphincter manometry, but no sphincterotomy
Study: NCT00647049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: 8000mg/m2 i.v., max. 2 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375mg/m2, max. 8 times

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375mg/m2, max. 8 times

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 3000mg/m2 die i.v., 2 days (max. 2 cycles)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 3000mg/m2 die i.v., 2 days (max. 2 cycles)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: 40mg/m2 i.v. (max. 2 cycles) 2 x 5mg/kg/die i.v. for 2 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: 40mg/m2 i.v. (max. 2 cycles) 2 x 5mg/kg/die i.v. for 2 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carmustin
Description: 400mg/m2 i.v. for 1 day
Study: NCT06574542

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Push enteroscopy (PE)
Description: All patients enrolled in this study underwent evaluation using push enteroscopy (PE)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Colonoscopy
Description: After push enteroscopy (PE), all patients subsequently underwent a colonoscopy on the same day or the next day. However, if a culprit lesion was identified during PE and the patient was considered at risk for undergoing colonoscopy, the colonoscopy was not performed and was presumed to be negative.
Study: NCT02127840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Synacthen infusion during adrenal venous sampling
Description: Adrenal venous sampling during Synacthen infusion
Study: NCT00647049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carmustin
Description: 400mg/m2 i.v. for 1 day
Study: NCT00526890

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: selenomethionine
Description: Oral Twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Weekly IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Weekly IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative Study

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergoing radiation Therapy
Study: NCT03389984

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: cutaneous
Description: SKIN BIOPSY
Study: NCT02785172

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IDP-118 Vehicle Lotion
Description: Vehicle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IDP-118 Vehicle Cream
Description: Vehicle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDP-118 Lotion
Description: Lotion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ultravate Cream
Description: Cream
Study: NCT00551122

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: lenograstim

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pegfilgrastim

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Study: NCT01760278

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: recombinant Follicle Stimulating Hormone (rFSH)
Description: There are two arms of the study. The Study arm and the Control arm. In each arm, subjects, after randomization, will be stimulated with rFSH 225IU/day.~On day 6, Cetrorelix 0.25mg/day to be added till the day of Ovitrell. Thereafter, ovum pick-up and embryo transfer to be done. Six weeks after transfer clinical pregnancy identified which will be the end-point of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant Follicle Stimulating Hormone (rFSH)
Description: There are two arms of the study. The Study arm and the Control arm. In each arm, subjects, after randomization, will be stimulated with rFSH 225IU/day.~On day 6, Cetrorelix 0.25mg/day to be added till the day of Ovitrell. Thereafter, ovum pick-up and embryo transfer to be done. Six weeks after transfer clinical pregnancy identified which will be the end-point of the study.
Study: NCT04211467

Intervention type: OTHER
Intervention: No Intervention
Description: There is no intervention for this study
Study: NCT04351295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Favipiravir
Description: Favipiravir

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroquine
Description: chloroquine oral tablets
Study: NCT03730324

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: mpMRI
Description: Study subjects will undergo urine and plasma biomarker testing and mpMRI prior to biopsy

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Urine and plasma biomarkes.
Description: Study subjects will undergo urine and plasma biomarker testing prior to standard biopsy
Study: NCT02933996

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TEAS+GA group
Description: The acupoints including Zusanli and Shenshu, were identified before electrical stimulation with surface electrodes. Selection of these acupoints was based on a consensus between the acupuncturists of the study.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham TEAS+GA group
Description: No electrical stimulation sensation is performed in the Sham TEAS group. In the Sham TEAS group, pseudo-stimulation is provided by deliberately connecting the electrodes to the incorrect output socket of the electroacupuncture device, and thus there is no flow of electric current. Patients could see the output light flashing but no current was transmitted throughout the procedure. Patients would be told that the stimulation frequency selected was not perceivable by human beings.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham TEAS+GA group
Description: No electrical stimulation sensation is performed in the Sham TEAS group. In the Sham TEAS group, pseudo-stimulation is provided by deliberately connecting the electrodes to the incorrect output socket of the electroacupuncture device, and thus there is no flow of electric current. Patients could see the output light flashing but no current was transmitted throughout the procedure. Patients would be told that the stimulation frequency selected was not perceivable by human beings.
Study: NCT01357564

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tailored Activity Program
Description: The interventionist, an occupational therapist, meets with the caregiver and introduces the intervention goals. The OT provides and reviews written educational materials about dementia, importance of taking care of self, communication strategies and other educational materials. Also provided and reviewed is The 36 Hour Day. The OT interviews the caregiver to obtain information about previous roles, habits, past and current daily routines, caregiver and Veteran preferences and interests. The OT also observes interactions, noting communication and management style. The OT will also meet with the Veteran, observe social capacity using the Peavy Comportment scale and administer the Dementia Rating Scale.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control
Description: Caregivers in this group received bi-weekly telephone contact by a trained healthcare professional. In each session, caregivers were provided information about dementia and strategies for disease management. Each telephone contact began with a brief overview the session purpose, followed by a description of key facts, and concluded with a question and answer period. The attention control group intervention was delivered by a member of the research team who is knowledgeable about dementia and has had prior experience working with family caregivers.
Study: NCT02809677

Intervention type: OTHER
Group type: OTHER
Intervention: Non-Interventional
Description: This is a 52 week non-placebo controlled and non-randomized clinical research study to see whether treating Major Depressive Disorder (MDD) in caregivers of children with asthma will improve asthma outcomes in children. Caregivers may choose to receive an antidepressant medication that is considered standard medical care for MDD, or may opt out of antidepressant treatment. No treatment is withheld from participants and no placebos are used, thus there is no active intervention in this study.
Study: NCT04978688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relugolix
Description: Administered as an oral tablet once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relugolix
Description: Administered as an oral tablet once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2/NETA
Description: Administered as an oral tablet once daily.
Study: NCT01889277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-3995-Low

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-3995-High

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03730324

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Urine and plasma biomarkes.
Description: Study subjects will undergo urine and plasma biomarker testing prior to standard biopsy
Study: NCT01745978

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Precut papillotomy
Study: NCT02550379

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Emotion Recognition Training

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Training
Study: NCT00826397

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Each acupuncture session will last approximately 45 minutes and includes standardized body treatment with an emphasis on affected joints.
Study: NCT01745978

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Precut papillotomy
Study: NCT01346410

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiotherapy
Description: Suggested fractionation is 20-25 Gy / 1 fraction OR 30-36 Gy / 3 fractions (10-12 Gy per fraction) OR 40-45 Gy / 5 fractions (8-9 Gy per fraction)
Study: NCT00979628

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sliding scale regular insulin (SSRI)
Description: four-time daily in patients with T2DM admitted to general medicine and surgery wards.
Study: NCT02037750

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LINKS
Description: In the LINKS, foster/kin parents will participate in weekly group meetings led by well-trained and supervised paraprofessional facilitators (school behavioral aids and foster parents) where the curriculum is based on parent management training (PMT). In previous studies, attendance at such groups has been high, averaging about 75-80%. Missed sessions will be made up with an in-person visit to the foster/kin home during the week of the original session. In addition, youth in the intervention condition will receive individual skill building sessions from a Life Skills Coach to increase their competency at goal setting, refusal skills, and peer relations.
Study: NCT03223935

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Corn nuts
Description: Roasted corn nut snack
Study: NCT00979628

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basal Bolus
Description: glargine once daily plus glulisine before meals (plus corrective doses of glulisine as needed)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basal Plus
Description: glargine once daily plus corrective doses of glulisine before meals and bedtime as needed
Study: NCT01044147

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VLM-S
Description: Online program for weight loss - standard

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VLM-M
Description: Online program for weight loss - modulated

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: OGR
Description: Online program for weight loss - resources
Study: NCT03787485

Intervention type: BEHAVIORAL
Intervention: LINKS
Description: The primary aim of LINKS is to create community-clinical linkages between three community health centers and their respective county health departments in southern Arizona. This study will also develop and evaluate a chronic disease and emotional well-being intervention that will connect clinic patients to community-centered, county-delivered, community health worker programs.
Study: NCT01191255

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ferric citrate, ca acetate, sevelamer carbonate, placebo
Description: All intervention doses will be based on serum phosphorus levels and/or drug label requirements

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ferric citrate, ca acetate, sevelamer carbonate, placebo
Description: All intervention doses will be based on serum phosphorus levels and/or drug label requirements

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ferric citrate, ca acetate, sevelamer carbonate, placebo
Description: All intervention doses will be based on serum phosphorus levels and/or drug label requirements
Study: NCT01087879

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desogestrel-Ethinyl Estradiol contraceptive pill
Description: 150 microg Desogestrel and 20 microg Ethinyl Estradiol combination. One pill once a day for 9 weeks, continual administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etonogestrel-Ethinyl Estradiol vaginal ring
Description: Etonogestrel-Ethinyl Estradiol vaginal ring, which consists of 11,7 mg etonogestrel and 2,7 mg ethinyl estradiol. It delivers 0,120 mg etonogestrel and 0,015 mg ethinyl estradiol per day. Treatment continues continual for 9 weeks and the vaginal ring is changed every three weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norelgestromin-Ethinyl Estradiol contraceptive patch
Description: A combination transdermal contraceptive patch with 6 mg of norelgestromin and 600 microg of ethinyl estradiol. It delivers 203 microg of norelgestromin and 33,9 microg ethinyl estradiol per day. A continual use of patch for 9 weeks and the patch is changed every week.
Study: NCT01333033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT scan

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo RT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo RT
Study: NCT01081028

Intervention type: OTHER
Intervention: First-line therapy
Description: As prescribed by treating physician

Intervention type: OTHER
Intervention: First-line therapy
Description: As prescribed by treating physician

Intervention type: DRUG
Intervention: Second-line Multiple Myeloma treatments
Description: As prescribed by the treating physician
Study: NCT03445559

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinical Order Check
Description: A Clinical Order Check is an evidence-based, systems-level method to affect significant behavior change. It addresses the intervention functions of education, enablement and incentivization which are effective methods to change behaviors driven by beliefs about capabilities, knowledge, social influences, beliefs about consequences, and environmental context and resources. All VA facilities currently use locally adapted clinical reminders. This strategy is technologically simple, straightforward, and is considered to be a best practice within the VA IT community. The reminder will be self-explanatory and non-intrusive to workflow.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Academic Detailing
Description: Academic detailing is an individual and facility-level intervention consistently shown to improve provider behavior. This strategy addresses the intervention functions of persuasion, coercion, modeling, and education which are effective methods for affecting behaviors driven by beliefs about capabilities, knowledge, social influences, beliefs about consequences, and environmental context and resources. During the meeting, the detailer will follow a script explaining that the visit is part of an experimental program to provide physicians with up-to-date, unbiased information about imaging to stage prostate cancer.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Audit and Feedback
Description: Audit and feedback is an effective, individual-level intervention for changing healthcare provider behavior, resulting in small but potentially clinically important benefits. Audit and feedback addresses the intervention functions of education, persuasion and incentivization, all of which are important for addressing beliefs about capabilities and consequences, knowledge, and social influence.
Study: NCT03572933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ganaxolone
Description: active drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: inactive
Study: NCT03231618

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 1. Low-fat and high-carbohydrate diet; 2. High-fat and low-carbohydrate diet; 3. High-protein and low-fat diet
Description: Every participate was provided with 3 types of diets in random order

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 1. Low-fat and high-carbohydrate diet; 2. High-fat and low-carbohydrate diet; 3. High-protein and low-fat diet
Description: Every participate was provided with 3 types of diets in random order
Study: NCT00131989

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00306384

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin
Description: Alogliptin tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin
Description: Alogliptin tablets.
Study: NCT03223935

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chickpeas
Description: Roasted chickpea snack

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yellow peas
Description: Roasted yellow pea snack

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pinto beans
Description: Roasted pinto bean snack

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soybeans
Description: Roasted soybean snack

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Almonds
Description: Roasted almond snack
Study: NCT00984399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vagifem® (vaginal 17β-estradiol) questionnaire & menopause symptom checklist
Description: The goal is to have 30 patients on letrozole and 30 on anastrozole who are initiated on vaginal estrogen for symptoms of urogenital atrophy. All subjects will receive 10mcg vaginal 17-β estradiol tablets. Each subject will serve as her own control. We will monitor serum estradiol and follicle stimulating hormone (FSH) levels closely from 0-24 weeks. We will measure serum estradiol and FSH levels at baseline, and subsequently at weeks 2, 7, 12, 18 and 24 after commencing therapy with 10mcg vaginal 17-β estradiol.
Study: NCT01198899

Intervention type: OTHER
Intervention: blood sampling
Description: Blood sampling will be used.
Study: NCT03979235

Intervention type: DIAGNOSTIC_TEST
Intervention: Motor function assessment
Description: perform motor function assessment by using scales, sEMG, and inertia sensors
Study: NCT03876080

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry needling
Description: The use of a solid filiform needle to treat trigger points

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham needling
Description: Simulated needling
Study: NCT03059108

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early Loading
Description: The procedure in this group will consist on placing implant-supported restorations over the implants placed 4 weeks earlier. The device (dental implant) is of the same type in both groups.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Loading
Description: The procedure in this group will consist on placing implant-supported restorations over the implants placed 8 weeks earlier. The device (dental implant) is of the same type in both groups.
Study: NCT01318226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATx08-001
Description: ATx08-001 will be administered as a 6mm white film coated tablet of 2.5 mg strength, to be taken orally at a dose of 2.5 mg or 7.5 mg, twice a day approximately every 12 hours over an 8 day period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATx08-001
Description: ATx08-001 will be administered as a 6mm white film coated tablet of 2.5 mg strength, to be taken orally at a dose of 2.5 mg or 7.5 mg, twice a day approximately every 12 hours over an 8 day period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered as a 6mm white film coated tablet, twice a day approximately every 12 hours over an 8 day period. Placebo is identical in appearance to the ATx 08-001 tablet.
Study: NCT00712023

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: warming device (a reusable, custom-made forced- air warming mattress)
Description: 2=forced-air warming mattress~1=circulating-water mattress